The University of Washington Addictions, Drug, and Alcohol Institute (UW ADAI), formerly the Alcohol & Drug Abuse Institute, is a multidisciplinary research institute at the University of Washington. UW established ADAI in October 1973 as a research institute for alcohol and drug use research at the university and in the northwest region. Grants and contracts from federal and state agencies and private foundations provide the majority of the Institute’s funding, which includes appropriations from the State’s Dedicated Cannabis Account.
Cannabinoid Hyperemesis Syndrome (CHS): Understanding an Emerging Public Health Challenge
- CReDO Founder/CEO Ethan Russo
This webinar will provide an overview of Cannabinoid hyperemesis syndrome (CHS), a constellation of intractable vomiting, and abdominal pain and hot bathing behavior that solely occurs in the context of certain heavy chronic use of THC-predominant cannabis ,including synthetic cannabinoids. Whereas multiple etiological theories of its causation have been advanced (e.g., pesticide or neem exposure), these have been largely debunked. CHS is associated with frequent emergency department visits with high associated expense (>$90K USD). Considerable morbidity and even some fatalities have been reported. The definitive treatment is abstention from cannabis usage, but parenteral haloperidol and cutaneous application of capsaicin ointment can provide symptomatic relief.
from the webinar registration description (March 6, 2025)
